Report On HOOKIPA Pharma Inc.’s (HOOK) Price Performance

The stock of HOOKIPA Pharma Inc. (NASDAQ:HOOK) decreased by -$0.02 on Wednesday to $1.69, down -1.17 percent. The last five days have seen an average of 647,628 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$0.6266. The average number of shares traded over the last 20 days was 568,292, while the average volume over the last 50 days totaled 637,761.

HOOK stock appreciated 12.50% since last month. On 05/25/22, the company’s shares reached a one-month low of $1.4600. The stock touched a high of $9.68 on 02/22/22, after rallying from a low of $1.25 in 52 weeks. The price of HOOK stock has declined by -26.61% or -$0.6266 this year, reaching a new high 4 times. Still, the stock price is down -82.54% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Insider Transactions

There have been 183 days since HOOKIPA Pharma Inc. (HOOK) last reported insider trading activity on Dec 21. On Dec 21, Chief Medical Officer Matushansky Igor sold 14,949 shares at $2.49 each. This transaction resulted in the insider making $37,223.

Financial Health

For the three months ended December 30, HOOKIPA Pharma Inc.’s quick ratio was 5.50, while its current ratio was 5.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending December 30 is 0.01, and the total debt to equity ratio is 0.04. Based on annual data, it had gross profit of $100.12 million and revenue of $18.45 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. HOOK’s return on assets (ROA) during the last 12 months has been -48.50%. There was a -86.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -64.80%.

Earnings Surprise

According to HOOKIPA Pharma Inc.’s quarterly financial report for the quarter that ended December 30. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.45 million, while revenues fell by -255.86% to $3.73 million. It was predicted that HOOKIPA Pharma Inc.’s quarterly earnings would be -$0.65, but it ended up being -$0.58, beating the consensus by -12.10%. EBITDA was -$19.07 million for the quarter. At the end of HOOKIPA Pharma Inc.’s most recent quarter ended December 30, its liabilities totaled 47.78 million, while its total debt was $10.62 million. Equity owned by shareholders amounts to $54.69 million.

Technical Picture

Here’s a quick look at HOOKIPA Pharma Inc.’s (HOOK) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 52.84%, suggesting the stock is Neutral, with a 69.75% historical volatility rate.

The stochastic %K and %D were 40.49% and 34.95% respectively, while the average true range (ATR) was 0.1522. Based on the 14-day stochastic reading of 45.61%, the RSI (14) reading is 52.54%. On the 9-day MACD Oscillator, the stock is at -0.0037, and the 14-day reading is at -0.0363.

Analyst Ratings

HOOKIPA Pharma Inc. (NASDAQ: HOOK) was downgraded by Morgan Stanley to a an Equal-weight rating in its latest research report. The stock was previously rated as a an Overweight.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam